Heval Mohamed Kelli, MD
Cardiovascular Disease · Lawrenceville, GANPI 1407114184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.1% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,424 and has fallen 57.8% since, to $601 in 2025.
Across 217 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$540
- Johnson & Johnson$370
- Amgen$353
- Intuitive Surgical$349
- AstraZeneca$333
- Boston Scientific$317
- plus $3K from 25 others
What the payments were for
- Travel & lodging$3497%
- Food & beverage$4,71993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $540 |
| Johnson & Johnson | 22 | $370 |
| Amgen | 20 | $353 |
| Intuitive Surgical | 2 | $349 |
| AstraZeneca | 18 | $333 |
| Boston Scientific | 10 | $317 |
| Abbott | 2 | $295 |
| Merck | 13 | $258 |
| Biotronik Inc. | 2 | $229 |
| Pfizer | 11 | $215 |
| Boehringer Ingelheim | 12 | $206 |
| E.r. Squibb & Sons, L.L.C. | 12 | $191 |
| Esperion Therapeutics, Inc. | 5 | $191 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $160 |
| Actelion Pharmaceuticals US, Inc. | 7 | $146 |
| Daiichi Sankyo Inc. | 6 | $136 |
| Edwards Lifesciences | 5 | $131 |
| Novo Nordisk | 4 | $83 |
| Cvrx, Inc. | 3 | $77 |
| Heartflow, Inc. | 4 | $68 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Chiesi USA, Inc. | 3 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Scpharmaceuticals Inc. | 2 | $45 |
| Lantheus Medical Imaging, Inc. | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Abiomed | 2 | $37 |
| Bayer | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$343
- AMPLATZER AMULET$167
- PK Papyrus$150
- Rivacor 7 DR-T$150
- Orsiro Mission$150
- BioMonitor$150
- Acticor 7 VR-T DX$150
- PORTICO$128
- NEXLETOL$125
How this compares
$5,068 in reported general payments places this provider in the 70th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 185 | $203,162 |
| XareltoRivaroxaban | 26 | $25,853 |
| JardianceEmpagliflozin | 18 | $19,781 |
| FarxigaDapagliflozin Propanediol | 16 | $18,327 |
| BrilintaTicagrelor | 13 | $10,129 |
| Nifedipine ErNifedipine | 124 | $4,282 |
| Metoprolol Succinate | 234 | $2,348 |
| Atorvastatin Calcium | 215 | $1,762 |
| Hydralazine Hcl | 118 | $1,663 |
| Isosorbide Dinitrate | 12 | $1,588 |
| Ranolazine ErRanolazine | 12 | $1,556 |
| Spironolactone | 59 | $1,146 |
| Losartan Potassium | 124 | $983 |
| Amlodipine Besylate | 169 | $803 |
| Carvedilol | 117 | $793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $215 | $203,162185 claims |
| AstraZenecaFarxiga, Brilinta | $333 | $28,45529 claims |
| Johnson & JohnsonXarelto | $370 | $25,85326 claims |
| Boehringer IngelheimJardiance | $206 | $19,78118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Lawrenceville
- Marc UntermanLawrenceville$40K
- Marcus SimsLawrenceville$32K
- Demir BaykalLawrenceville$26K
- Edward ClermontLawrenceville$16K
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.